https://ferringusa.com/?post_type=press 2026-05-17T11:01:51+00:00 https://ferringusa.com/?press=ferring-and-rebiotix-present-positive-interim-phase-3-results-from-open-label-study-of-investigational-microbiota-based-live-biotherapeutic-rbx2660-at-digestive-disease-week-ddw 2021-08-20T14:02:52+00:00 https://ferringusa.com/?press=chrissy-teigen-launches-fertility-out-loud-campaign-to-empower-those-with-fertility-challenges-to-get-the-help-they-need 2021-08-20T14:02:53+00:00 https://ferringusa.com/?press=ferring-and-rebiotix-to-present-landmark-data-for-investigational-microbiota-based-live-biotherapeutic-rbx2660-at-digestive-disease-week-ddw-2021 2021-08-20T14:02:53+00:00 https://ferringusa.com/?press=ferring-and-rebiotix-present-landmark-phase-3-data-demonstrating-superior-efficacy-of-investigational-rbx2660-versus-placebo-to-reduce-recurrence-of-c-difficile-infection 2021-08-20T14:02:53+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-to-share-new-reproductive-medicine-data-at-asrm-2020-scientific-congress-expo 2021-08-20T14:02:54+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-to-present-new-microbiome-research-data-at-idweek-2020 2021-08-20T14:02:54+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-supports-official-proclamation-of-november-as-clostridioides-difficile-infection-awareness-month-in-states-of-new-jersey-and-minnesota 2021-08-20T14:02:54+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-secures-preferred-access-for-orthopaedic-gastroenterology-treatments-through-cvs-health-and-aetna-pharmacy-benefit 2021-08-20T14:02:54+00:00 https://ferringusa.com/?press=rebiotix-and-ferring-announce-worlds-first-with-positive-preliminary-pivotal-phase-3-data-for-investigational-microbiome-based-therapy-rbx2660 2021-08-20T14:02:56+00:00 https://ferringusa.com/?press=new-clinical-data-published-on-menopur-menotropins-for-injection-in-a-predicted-high-responder-population 2021-08-20T14:02:56+00:00 https://ferringusa.com/?press=brent-ragans-named-president-of-ferring-us 2021-08-20T14:02:56+00:00 https://ferringusa.com/?press=ucb-and-ferring-pharmaceuticals-announce-co-promotion-of-cimzia-certolizumab-pegol-for-the-treatment-of-adults-with-moderate-to-severe-crohns-disease 2021-08-20T14:02:56+00:00 https://ferringusa.com/?press=ortikos-budesonide-the-first-and-only-once-daily-dose-for-treatment-of-mild-to-moderate-crohns-disease-now-available-in-the-u-s 2021-08-20T14:02:56+00:00 https://ferringusa.com/?press=ferring-us-issues-voluntary-nationwide-recall-of-ddavp-nasal-spray-10-mcg-0-1ml-desmopressin-acetate-nasal-spray-10-mcg-0-1ml-stimate-nasal-spray-1-5-mg-ml-due-to-superpotency 2021-08-20T14:02:56+00:00 https://www.ferringusa.com/screen-shot-2020-08-05-at-3-34-02-pm-817x1024 https://ferringusa.com/?press=fergene-announces-pivotal-phase-3-study 2021-08-20T14:02:58+00:00 https://www.ferringusa.com/12-5-19-fergene-press-release-efficacy-table https://ferringusa.com/?press=fertility-housecalls 2021-08-20T14:02:58+00:00 https://ferringusa.com/?press=ferring-and-blackstone-life-sciences-invest-over-570-million-usd-in-novel-gene-therapy-for-bladder-cancer-patients 2021-08-20T14:02:59+00:00 https://ferringusa.com/?press=nocdurna-desmopressin-acetate-sublingual-tablets-now-available-by-prescription-in-us-for-treatment-of-nocturia-due-to-nocturnal-polyuria 2021-08-20T14:03:04+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-enters-exclusive-agreement-with-invo-bioscience-to-commercialize-the-novel-invocell-system-for-use-in-the-treatment-of-infertility 2021-08-20T14:03:04+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-adds-two-products-to-its-robust-reproductive-health-portfolio-in-the-u-s 2021-08-20T14:03:04+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-appoints-sophie-opdyke-to-lead-its-new-u-s-oncology-division 2021-08-20T14:03:04+00:00 https://ferringusa.com/?press=response-to-fda-safety-alert-regarding-the-use-of-fecal-microbiota-for-transplantation 2021-08-20T14:03:04+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-to-present-new-fertility-data-at-asrm-2019-scientific-congress-expo 2021-08-20T14:03:04+00:00 https://ferringusa.com/?press=fda-approves-ferrings-clenpiq-sodium-picosulfate-magnesium-oxide-and-anhydrous-citric-acid-oral-solution-for-colonoscopy-prep 2021-08-20T14:03:05+00:00 https://ferringusa.com/?press=ferrings-zomacton-somatropin-for-injection-receives-fda-approval-to-treat-growth-hormone-deficiency-in-adults 2021-08-20T14:03:05+00:00 https://ferringusa.com/?press=ferrings-clenpiq-sodium-picosulfate-magnesium-oxide-and-anhydrous-citric-acid-oral-solution-for-colonoscopy-prep-now-available 2021-08-20T14:03:05+00:00 https://ferringusa.com/?press=ferring-acquires-innovative-biotechnology-company-and-microbiome-pioneer-rebiotix-inc 2021-08-20T14:03:05+00:00 https://ferringusa.com/?press=ferring-signs-global-agreement-to-commercialise-novel-gene-therapy-for-bladder-cancer-patients 2021-08-20T14:03:05+00:00 https://ferringusa.com/?press=nocdurna-desmopressin-acetate-now-approved-by-u-s-fda-as-first-sublingual-tablet-to-treat-nocturia-due-to-nocturnal-polyuria 2021-08-20T14:03:05+00:00 https://ferringusa.com/?press=ferrings-heat-stable-carbetocin-could-save-thousands-of-womens-lives-by-preventing-excessive-bleeding-after-childbirth 2021-08-20T14:03:05+00:00 https://ferringusa.com/?press=ferring-and-celmatix-launch-ambitious-genomics-collaboration-to-advance-care-in-reproductive-medicine-and-womens-health 2021-08-20T14:03:05+00:00 https://ferringusa.com/?press=ferring-introduces-zoma-jet-10-a-new-needle-free-delivery-system-for-patients-treated-with-zomacton-10mg 2021-08-20T14:03:05+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-launches-two-new-resources-to-help-women-struggling-with-infertility-during-national-infertility-awareness-week 2021-08-20T14:03:06+00:00 https://ferringusa.com/?press=ferring-appoints-aaron-graff-to-executive-board 2021-08-20T14:03:06+00:00 https://ferringusa.com/?press=paul-navarre-joins-ferring-pharmaceuticals-as-chief-executive-officer-of-ferring-holding-inc 2021-08-20T14:03:06+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-to-donate-25000-to-hurricane-harvey-relief 2021-08-20T14:03:06+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-presents-new-data-comparing-menopur-menotropins-for-injection-to-rfsh-in-high-responder-patients 2021-08-20T14:03:06+00:00 https://ferringusa.com/?press=couples-inspiring-video-on-overcoming-infertility-fighting-cancer-wins-educational-grant 2021-08-20T14:03:07+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-and-national-style-expert-bobbie-thomas-launch-the-fertility-facts-know-more-start-asking-campaign-during-national-infertility-awareness-week 2021-08-20T14:03:07+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-acquires-exclusive-licensing-rights-to-condoliase-from-seikagaku-corporation 2021-08-20T14:03:07+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-recognized-as-the-nations-most-adoption-friendly-workplace-by-dave-thomas-foundation-for-adoption 2021-08-20T14:03:07+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-highlights-ongoing-sponsorship-of-arthritis-foundation-through-fundraising-events 2021-08-20T14:03:07+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-moves-forward-with-early-stage-development-of-bacteriophage-therapy-for-inflammatory-bowel-disease 2021-08-20T14:03:08+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-acquires-global-rights-to-milprosa-progesterone-vaginal-ring 2021-08-20T14:03:08+00:00 https://ferringusa.com/?press=ferring-research-institute-inc-announces-recipients-of-ferring-innovation-grants 2021-08-20T14:03:08+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-named-as-national-sponsor-of-arthritis-foundation-fundraising-events 2021-08-20T14:03:08+00:00 https://ferringusa.com/?press=ferring-names-aaron-graff-as-chief-executive-officer-of-us-holding-company 2021-08-20T14:03:08+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-moves-to-strengthen-growth-with-appointment-of-chief-medical-and-chief-scientific-officers 2021-08-20T14:03:09+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-receives-fda-approval-for-growth-hormone-name-change-acquires-zomacton-somatropin-rdna-origin-for-injection-and-needle-free-device-in-the-u-s 2021-08-20T14:03:09+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-launches-2015-heart-to-heart-video-contest-supporting-families-whove-overcome-infertility 2021-08-20T14:03:09+00:00 https://ferringusa.com/?press=ferring-to-present-clinical-data-on-efficacy-and-safety-of-clenpiqtm-sodium-picosulfate-magnesium-oxide-and-anhydrous-citric-acid-oral-solution-for-colonoscopy-prep-at-digestive-disease-week 2021-09-03T09:56:32+00:00 https://ferringusa.com/?press=study-reveals-nocturia-drains-nearly-215-billion-from-the-u-s-economy 2021-09-03T09:58:28+00:00 https://ferringusa.com/?press=fda-approves-new-indications-for-zomacton-somatropin-as-ferring-plans-launch-of-needle-free-delivery-system 2021-09-03T10:02:31+00:00 https://ferringusa.com/?press=fertility-house-calls-now-available-nationwide-to-help-women-and-couples-take-the-first-steps-to-parenthood-virtually 2021-09-21T11:23:52+00:00 https://ferringusa.com/?press=ferring-to-present-award-winning-landmark-research-for-investigational-microbiota-based-live-biotherapeutic-rbx2660-at-idweek-2021 2021-09-21T17:08:42+00:00 https://ferringusa.com/?press=ferring-presents-complete-data-across-five-rbx2660-trials-demonstrating-consistent-and-durable-efficacy-in-recurrent-c-difficile-infection-as-well-as-multiple-analyses-demonstrating-positive-shifts 2021-09-30T12:36:54+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-to-present-new-reproductive-medicine-data-at-asrm-2021-scientific-congress-expo 2021-10-14T12:14:51+00:00 https://ferringusa.com/?press=ferring-to-present-award-winning-real-world-outcomes-analysis-for-investigational-microbiota-based-live-biotherapeutic-rbx2660-in-patients-with-recurrent-c-difficile-infection-and-ibd-at-acg-2021 2021-10-18T12:02:06+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-supports-the-proclamation-of-november-as-clostridioides-difficile-infection-awareness-month-in-new-jersey-and-minnesota 2021-11-11T17:23:23+00:00 https://ferringusa.com/?press=ferring-presents-award-winning-real-world-outcomes-analysis-for-investigational-microbiota-based-live-biotherapeutic-rbx2660-at-acg-2021 2022-01-12T04:46:31+00:00 https://ferringusa.com/?press=ferring-announces-investment-in-robyn-an-online-community-that-provides-access-to-fertility-and-parental-wellness-resources 2022-02-15T13:29:58+00:00 https://ferringusa.com/?press=data-for-ferrings-rbx2660-published-in-bmc-infectious-diseases-durable-reduction-of-clostridioides-difficile-infection-recurrence-and-microbiome-restoration-after-treatment-with-rbx2660-r 2022-03-21T04:50:49+00:00 https://ferringusa.com/?press=ferring-to-present-analyses-for-investigational-microbiota-based-live-biotherapeutic-rbx2660-in-patients-with-recurrent-c-difficile-infection-at-ddw-2022 2022-05-11T12:00:00+00:00 https://ferringusa.com/?press=ferring-presents-new-analyses-of-efficacy-safety-and-microbiome-composition-data-at-ddw-2022-for-rbx2660-its-investigational-microbiota-based-live-biotherapeutic 2022-05-24T17:38:24+00:00 https://ferringusa.com/?press=ferring-announces-u-s-fda-advisory-committee-meeting-for-rbx2660-its-investigational-microbiota-based-live-biotherapeutic 2022-08-09T11:16:26+00:00 https://ferringusa.com/?press=ferring-to-present-analyses-for-investigational-microbiota-based-live-biotherapeutic-rbx2660-in-patients-with-recurrent-c-difficile-infection-at-acg-2022 2022-10-11T12:49:30+00:00 https://ferringusa.com/?press=ferring-to-present-analyses-for-investigational-microbiota-based-live-biotherapeutic-rbx2660-in-patients-with-recurrent-c-difficile-infection-at-idweek-2022 2022-10-18T17:29:24+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-to-present-new-data-highlighting-future-assisted-reproductive-technology-market-trends-at-asrm-2022-scientific-congress-expo 2022-10-19T13:29:06+00:00 https://ferringusa.com/?press=ferring-presents-new-subgroup-analyses-of-health-related-quality-of-life-and-safety-and-efficacy-data-at-idweek-2022-for-rbx2660 2022-10-20T11:05:23+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-announces-the-launch-of-fertilitywise-a-new-on-demand-e-learning-program-for-fertility-clinic-staff 2022-10-21T14:22:15+00:00 https://ferringusa.com/?press=ferring-presents-seven-new-analyses-at-acg-2022-for-rbx2660-its-investigational-microbiota-based-live-biotherapeutic 2022-10-24T12:06:42+00:00 https://ferringusa.com/?press=partnering-to-help-drive-reproductive-medicine-and-maternal-health-forward 2022-10-31T19:46:43+00:00 https://ferringusa.com/?press=pivotal-phase-3-efficacy-and-safety-data-for-ferrings-rbx2660-published-in-drugs 2022-11-07T15:44:05+00:00 https://ferringusa.com/?press=ferring-appreciates-ongoing-support-from-new-jersey-and-minnesota-as-both-states-issue-proclamations-recognizing-november-as-c-difficile-infection-awareness-month 2022-11-28T14:29:55+00:00 https://ferringusa.com/?press=ferring-receives-u-s-fda-approval-for-rebyota-fecal-microbiota-live-jslm-a-novel-first-in-class-microbiota-based-live-biotherapeutic 2022-12-12T17:56:35+00:00 https://ferringusa.com/?press=ferring-receives-approval-from-u-s-fda-for-adstiladrin-for-high-risk-bcg-unresponsive-non-muscle-invasive-bladder-cancer 2022-12-16T20:28:14+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-announces-availability-of-rebyota-fecal-microbiota-live-jslm-the-first-and-only-fda-approved-microbiome-based-treatment-for-the-prevention-of-r 2023-02-14T13:42:15+00:00 https://ferringusa.com/?press=ferring-introduces-fertility-outreach-a-text-based-platform-providing-aspiring-parents-with-access-to-a-live-fertility-coach 2023-02-22T17:34:43+00:00 https://ferringusa.com/?press=frontiers-in-microbiology-publishes-article-detailing-novel-microbiome-based-biomarker-of-post-antibiotic-disruptions-in-gut-microbiota 2023-03-02T19:37:49+00:00 https://ferringusa.com/?press=retrospective-analysis-of-data-evaluating-safety-and-efficacy-of-rebyota-fecal-microbiota-live-jslm-in-a-real-world-patient-population-with-comorbidities-and-risk-factors-publish 2023-05-04T12:17:51+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-recognizes-national-infertility-awareness-week 2023-05-04T12:19:20+00:00 https://ferringusa.com/?press=ferring-to-present-analyses-of-data-for-rebyota-fecal-microbiota-live-jslm-the-first-fda-approved-microbiome-based-treatment-for-the-prevention-of-recurrent-c-difficile-infecti 2023-05-04T12:19:47+00:00 https://ferringusa.com/?press=four-analyses-of-data-for-rebyota-fecal-microbiota-live-jslm-the-first-fda-approved-microbiome-based-treatment-for-the-prevention-of-recurrent-c-difficile-infection-presented 2023-05-18T19:40:14+00:00 https://ferringusa.com/?press=ferring-receives-positive-vote-from-u-s-fda-advisory-committee-for-rbx2660 2023-05-19T01:51:45+00:00 https://ferringusa.com/?press=ferring-announces-positive-topline-phase-3-results-for-si-6603-an-investigational-treatment-for-lumbar-disc-herniation 2023-05-26T12:53:09+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-receives-u-s-fda-approval-of-drug-substance-manufacturing-scale-up-process-for-gene-therapy-adstiladrin-nadofaragene-firadenovec-vncg 2023-06-12T20:39:20+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-on-track-to-deliver-adstiladrin-nadofaragene-firadenovec-vncg-to-patients-in-early-experience-program-in-september-2023 2023-06-26T12:03:29+00:00 https://ferringusa.com/?press=largest-integrated-safety-analysis-from-five-prospective-clinical-trials-for-rebyota-fecal-microbiota-live-jslm-published-in-therapeutic-advances-in-gastroenterology 2023-07-11T13:01:51+00:00 https://ferringusa.com/?press=royalty-pharma-and-ferring-pharmaceuticals-enter-into-us-500-million-royalty-agreement-for-new-intravesical-gene-therapy-adstiladrin-nadofaragene-firadenovec-vncg 2023-08-24T14:39:29+00:00 https://ferringusa.com/?press=first-bladder-cancer-patient-dosed-with-commercially-available-intravesical-gene-therapy-adstiladrin-nadofaragene-firadenovec-vncg 2023-09-12T12:48:45+00:00 https://ferringusa.com/?press=ferring-to-present-new-data-analyses-at-idweek-2023-for-rebyota-fecal-microbiota-live-jslm-the-first-and-only-single-dose-fda-approved-microbiome-based-treatment-for-the-preventio 2023-09-21T12:01:51+00:00 https://ferringusa.com/?press=ferring-named-in-fortunes-2023-change-the-world-list 2023-09-28T13:01:49+00:00 https://ferringusa.com/?press=ferring-to-present-new-data-analyses-at-acg-2023-for-rebyota-fecal-microbiota-live-jslm-the-first-and-only-single-dose-fda-approved-microbiome-based-treatment-for-the-prevention-o 2023-10-03T12:08:26+00:00 https://ferringusa.com/?press=more-real-world-data-and-new-analyses-of-data-for-rebyota-fecal-microbiota-live-jslm-presented-at-idweek-2023 2023-10-11T12:11:18+00:00 https://ferringusa.com/?press=asrm-announces-historic-5-million-endowment-from-ferring-pharmaceuticals 2023-10-16T15:12:16+00:00 https://ferringusa.com/?press=acg-2023-presentations-for-rebyota-fecal-microbiota-live-jslm-explore-association-between-gut-microbiome-composition-and-health-related-quality-of-life-and-evaluate-efficacy-and-saf 2023-10-23T12:02:40+00:00 https://ferringusa.com/?press=ferring-praises-support-from-new-jersey-and-minnesota-as-both-states-issue-proclamations-recognizing-november-as-c-difficile-infection-awareness-month-for-fourth-consecutive-year 2023-11-15T13:01:53+00:00 https://ferringusa.com/?press=new-data-show-durable-response-following-treatment-with-adstiladrin-nadofaragene-firadenovec-vncg 2023-11-29T13:00:26+00:00 https://ferringusa.com/?press=new-docuseries-explores-the-diverse-experiences-and-emotional-realities-faced-by-many-on-the-path-to-parenthood 2023-11-29T15:30:38+00:00 https://ferringusa.com/?press=phase-4-study-evaluating-use-of-adstiladrin-nadofaragene-firadenovec-vncg-in-real-world-setting 2024-01-24T13:04:38+00:00 https://ferringusa.com/?press=three-year-follow-up-data-in-bcg-unresponsive-nmibc-show-durable-response-to-treatment-with-adstiladrin-nadofaragene-firadenovec-vncg-in-two-patient-cohorts 2024-04-08T12:10:30+00:00 https://ferringusa.com/?press=ferring-presents-pivotal-phase-3-efficacy-and-safety-data-for-investigational-treatment-si-6603-condoliase-in-lumbar-disc-herniation-at-asipp-2024 2024-04-08T15:00:33+00:00 https://ferringusa.com/?press=ferring-adds-three-new-studies-to-non-muscle-invasive-bladder-cancer-clinical-trial-program-with-adstiladrin-nadofaragene-firadenovec-vncg 2024-04-16T12:50:54+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-and-sk-pharmteco-enter-into-commercial-gene-therapy-manufacturing-deal 2024-04-18T13:08:52+00:00 https://ferringusa.com/?press=final-five-year-analysis-of-phase-3-data-with-adstiladrin-nadofaragene-firadenovec-vncg-shows-durable-bladder-preservation-and-consistent-long-term-safety-in-bcg-unresponsive-nmibc 2024-05-06T12:07:03+00:00 https://ferringusa.com/?press=ferring-announces-u-s-fda-acceptance-of-biologics-license-application-submission-for-si-6603-an-investigational-therapy-in-lumbar-disc-herniation 2024-05-14T13:03:03+00:00 https://ferringusa.com/?press=first-real-world-outcomes-data-and-new-analyses-of-data-for-rebyota-fecal-microbiota-live-jslm-presented-at-ddw-2024 2024-05-20T13:00:55+00:00 https://ferringusa.com/?press=ferring-position-on-alabama-supreme-court-ruling-in-lepage-v-mobile-infirmary-clinic 2024-06-06T21:06:33+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-and-posterity-health-launch-new-partnership-to-activate-men-about-their-fertility 2024-06-20T12:03:07+00:00 https://ferringusa.com/?press=ferring-presents-early-response-data-from-pivotal-phase-3-trial-for-investigational-treatment-si-6603-condoliase-in-lumbar-disc-herniation-at-aspn-2024 2024-07-15T12:00:11+00:00 https://ferringusa.com/?press=ferring-to-present-new-data-analyses-at-aspn-2024-for-si-6603-an-investigational-treatment-for-lumbar-disc-herniation 2024-07-29T17:02:19+00:00 https://ferringusa.com/?press=ferring-to-present-new-data-analysis-at-nass-2024-for-si-6603-an-investigational-treatment-for-lumbar-disc-herniation 2024-09-09T12:01:15+00:00 https://ferringusa.com/?press=ferring-presents-efficacy-and-safety-data-from-two-phase-3-studies-for-investigational-treatment-si-6603-condoliase-in-lumbar-disc-herniation-at-nass-2024 2024-09-25T12:02:16+00:00 https://ferringusa.com/?press=ferring-presents-real-world-outcomes-data-analyses-for-rebyota-fecal-microbiota-live-jslm-at-idweek-2024 2024-10-16T12:00:45+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-illustrates-strong-commitment-to-advancing-fertility-care-at-2024-american-society-for-reproductive-medicine-annual-congress 2024-10-18T12:09:24+00:00 https://ferringusa.com/?press=ferring-presents-new-data-analyses-for-rebyota-fecal-microbiota-live-jslm-at-acg-2024 2024-10-28T12:00:34+00:00 https://ferringusa.com/?press=ferring-appreciates-the-support-of-new-jersey-and-minnesota-as-they-issue-proclamations-recognizing-november-as-c-difficile-infection-awareness-month-for-fifth-consecutive-year 2024-11-13T15:02:41+00:00 https://ferringusa.com/?press=ferring-announces-u-s-fda-advisory-committee-meeting-for-si-6603-condoliase-an-investigational-treatment-in-lumbar-disc-herniation 2024-12-02T14:03:05+00:00 https://ferringusa.com/?press=ferring-advances-three-studies-in-adstiladrin-nadofaragene-firadenovec-vncg-clinical-trial-program 2025-01-16T20:32:51+00:00 https://ferringusa.com/?press=ferring-highlights-commitment-to-c-diff-infection-community-on-the-second-anniversary-of-the-launch-of-rebyota-fecal-microbiota-live-jslm 2025-01-27T14:04:42+00:00 https://ferringusa.com/?press=first-real-world-outcomes-data-for-adstiladrin-nadofaragene-firadenovec-vncg-to-be-presented-at-2025-asco-genitourinary-cancers-symposium 2025-02-12T13:53:57+00:00 https://ferringusa.com/?press=presidential-executive-order-on-in-vitro-fertilization 2025-03-04T00:31:22+00:00 https://ferringusa.com/?press=ferring-unveils-new-data-with-adstiladrin-nadofaragene-firadenovec-vncg-at-112th-annual-meeting-of-the-japanese-urological-association 2025-04-22T12:36:23+00:00 https://ferringusa.com/?press=u-s-fda-approves-second-drug-product-manufacturing-facility-for-adstiladrin-nadofaragene-firadenovec-vncg 2025-04-24T12:34:33+00:00 https://ferringusa.com/?press=ferring-presents-new-phase-3b-safety-and-effectiveness-data-for-recurrent-c-diff-patients-receiving-rebyota-fecal-microbiota-live-jslm-via-colonoscopy-and-additional-analyses-at-d 2025-05-05T13:09:16+00:00 https://ferringusa.com/?press=ferring-announces-full-availability-of-adstiladrin-nadofaragene-firadenovec-vncg-in-the-u-s 2025-07-08T18:57:30+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-recognizes-world-ivf-day-by-partnering-with-notable-advocates-to-amplify-the-conversation-about-infertility 2025-07-21T12:02:59+00:00 https://ferringusa.com/?press=ferring-expands-growing-body-of-real-world-evidence-reinforcing-use-of-adstiladrin-nadofaragene-firadenovec-vncg-in-urology-practices 2025-10-16T18:58:47+00:00 https://ferringusa.com/?press=ferring-presents-new-real-world-rebyota-fecal-microbiota-live-jslm-data-underscoring-effectiveness-and-significant-improvements-in-patient-quality-of-life 2025-10-20T13:32:31+00:00 https://ferringusa.com/?press=ferring-presents-new-data-analyses-for-rebyota-fecal-microbiota-live-jslm-at-acg-2025 2025-10-27T12:30:58+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-presents-two-new-analyses-of-pivotal-trial-data-for-follitropin-delta-fe-999049-at-asrm-2025 2025-10-27T17:10:15+00:00 https://ferringusa.com/?press=ferring-highlights-new-real-world-research-with-adstiladrin-nadofaragene-firadenovec-vncg-in-clinical-practice 2025-10-28T12:16:47+00:00 https://ferringusa.com/?press=ferring-applauds-new-jersey-and-michigan-for-proclamations-recognizing-november-as-c-difficile-infection-awareness-month 2025-11-12T22:16:26+00:00 https://ferringusa.com/?press=suo-and-ferring-pharmaceuticals-announce-the-suo-non-muscle-invasive-bladder-cancer-nmibc-fellows-research-grant 2025-12-02T18:10:43+00:00 https://ferringusa.com/?press=ferring-pharmaceuticals-and-theralase-technologies-announce-clinical-development-agreement-to-investigate-combination-therapy-in-bladder-cancer 2026-03-20T13:05:23+00:00 https://ferringusa.com/?press=u-s-fda-approves-label-update-to-accelerate-thaw-time-for-adstiladrin-nadofaragene-firadenovec-vncg 2026-03-24T19:15:43+00:00 https://ferringusa.com/?press=ferring-announces-update-to-nccn-guidelines-expanding-category-2a-recommendation-for-nadofaragene-firadenovec-vncg-adstiladrin-in-patients-with-bcg-unresponsive-nmibc 2026-03-30T14:27:58+00:00 https://ferringusa.com/?press=new-real-world-case-series-examines-re-induction-with-adstiladrin-nadofaragene-firadenovec-vncg-in-clinical-practice 2026-05-17T11:01:51+00:00